Enucleation for retinoblastoma: The experience of a single center in Jordan

Iyad Sultan, Matthew Wilson, Ibrahim Nawaiseh, Mustafa Mehyar, Saamir Kharma, Mohammed Al-Qudimat, Ribhi Hazin, Arwa Alalami, Imad Jaradat, Maysa Al-Husseini, Ghadeer Abdeen, Carlos Rodriguez-Galindo, Ibrahim Qaddoumi

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Despite multiple advances in the management of retinoblastoma, enucleation remains an essential therapeutic modality. We studied patients who underwent enucleation at the King Hussein Cancer Center in Jordan. We retrospectively reviewed medical records of children with retinoblastoma who were treated at our center from June 2002 to February 2008. Twenty-eight eyes from 27 patients were enucleated. Median age at diagnosis was 1.1 years (range, 0.3-6.3 years). Twenty-six eyes (93%) had advanced disease (RE groups IV and V). Seventeen patients (61%) had unilateral retinoblastoma, and 11 (39%) had bilateral retinoblastoma. The median time from diagnosis to enucleation was 0.45 months (range, 0-45 months; mean, 4.4 months) and was longer for patients with bilateral retinoblastoma (median, 2.2 vs. 0.2 months; P = 0.034). Twenty enucleated eyes (71%) did not show high-risk pathologic features. Seventeen eyes with advanced intraocular disease were enucleated atthe time of presentation, whereas chemoreduction was attempted for the other 19 eyes with advanced intraocular disease. Enucleation was then recommended for nine (47%) of those eyes. Enucleation at the time of diagnosis was feasible for most patients with advanced disease. Attempted salvage of eyes with advanced disease is justified, particularly in patients with bilateral disease. We were able to salvage almost half of these eyes. We hope our study provides new insights for counseling patients.

Original languageEnglish (US)
Pages (from-to)407-414
Number of pages8
JournalInternational Ophthalmology
Volume30
Issue number4
DOIs
StatePublished - Aug 1 2010

Fingerprint

Jordan
Retinoblastoma
Medical Records
Counseling

All Science Journal Classification (ASJC) codes

  • Ophthalmology

Cite this

Sultan, I., Wilson, M., Nawaiseh, I., Mehyar, M., Kharma, S., Al-Qudimat, M., ... Qaddoumi, I. (2010). Enucleation for retinoblastoma: The experience of a single center in Jordan. International Ophthalmology, 30(4), 407-414. https://doi.org/10.1007/s10792-010-9370-3

Enucleation for retinoblastoma : The experience of a single center in Jordan. / Sultan, Iyad; Wilson, Matthew; Nawaiseh, Ibrahim; Mehyar, Mustafa; Kharma, Saamir; Al-Qudimat, Mohammed; Hazin, Ribhi; Alalami, Arwa; Jaradat, Imad; Al-Husseini, Maysa; Abdeen, Ghadeer; Rodriguez-Galindo, Carlos; Qaddoumi, Ibrahim.

In: International Ophthalmology, Vol. 30, No. 4, 01.08.2010, p. 407-414.

Research output: Contribution to journalArticle

Sultan, I, Wilson, M, Nawaiseh, I, Mehyar, M, Kharma, S, Al-Qudimat, M, Hazin, R, Alalami, A, Jaradat, I, Al-Husseini, M, Abdeen, G, Rodriguez-Galindo, C & Qaddoumi, I 2010, 'Enucleation for retinoblastoma: The experience of a single center in Jordan', International Ophthalmology, vol. 30, no. 4, pp. 407-414. https://doi.org/10.1007/s10792-010-9370-3
Sultan, Iyad ; Wilson, Matthew ; Nawaiseh, Ibrahim ; Mehyar, Mustafa ; Kharma, Saamir ; Al-Qudimat, Mohammed ; Hazin, Ribhi ; Alalami, Arwa ; Jaradat, Imad ; Al-Husseini, Maysa ; Abdeen, Ghadeer ; Rodriguez-Galindo, Carlos ; Qaddoumi, Ibrahim. / Enucleation for retinoblastoma : The experience of a single center in Jordan. In: International Ophthalmology. 2010 ; Vol. 30, No. 4. pp. 407-414.
@article{1fe3348465b14ae8b0a501b9951ac570,
title = "Enucleation for retinoblastoma: The experience of a single center in Jordan",
abstract = "Despite multiple advances in the management of retinoblastoma, enucleation remains an essential therapeutic modality. We studied patients who underwent enucleation at the King Hussein Cancer Center in Jordan. We retrospectively reviewed medical records of children with retinoblastoma who were treated at our center from June 2002 to February 2008. Twenty-eight eyes from 27 patients were enucleated. Median age at diagnosis was 1.1 years (range, 0.3-6.3 years). Twenty-six eyes (93{\%}) had advanced disease (RE groups IV and V). Seventeen patients (61{\%}) had unilateral retinoblastoma, and 11 (39{\%}) had bilateral retinoblastoma. The median time from diagnosis to enucleation was 0.45 months (range, 0-45 months; mean, 4.4 months) and was longer for patients with bilateral retinoblastoma (median, 2.2 vs. 0.2 months; P = 0.034). Twenty enucleated eyes (71{\%}) did not show high-risk pathologic features. Seventeen eyes with advanced intraocular disease were enucleated atthe time of presentation, whereas chemoreduction was attempted for the other 19 eyes with advanced intraocular disease. Enucleation was then recommended for nine (47{\%}) of those eyes. Enucleation at the time of diagnosis was feasible for most patients with advanced disease. Attempted salvage of eyes with advanced disease is justified, particularly in patients with bilateral disease. We were able to salvage almost half of these eyes. We hope our study provides new insights for counseling patients.",
author = "Iyad Sultan and Matthew Wilson and Ibrahim Nawaiseh and Mustafa Mehyar and Saamir Kharma and Mohammed Al-Qudimat and Ribhi Hazin and Arwa Alalami and Imad Jaradat and Maysa Al-Husseini and Ghadeer Abdeen and Carlos Rodriguez-Galindo and Ibrahim Qaddoumi",
year = "2010",
month = "8",
day = "1",
doi = "10.1007/s10792-010-9370-3",
language = "English (US)",
volume = "30",
pages = "407--414",
journal = "International Ophthalmology",
issn = "0165-5701",
publisher = "Springer Netherlands",
number = "4",

}

TY - JOUR

T1 - Enucleation for retinoblastoma

T2 - The experience of a single center in Jordan

AU - Sultan, Iyad

AU - Wilson, Matthew

AU - Nawaiseh, Ibrahim

AU - Mehyar, Mustafa

AU - Kharma, Saamir

AU - Al-Qudimat, Mohammed

AU - Hazin, Ribhi

AU - Alalami, Arwa

AU - Jaradat, Imad

AU - Al-Husseini, Maysa

AU - Abdeen, Ghadeer

AU - Rodriguez-Galindo, Carlos

AU - Qaddoumi, Ibrahim

PY - 2010/8/1

Y1 - 2010/8/1

N2 - Despite multiple advances in the management of retinoblastoma, enucleation remains an essential therapeutic modality. We studied patients who underwent enucleation at the King Hussein Cancer Center in Jordan. We retrospectively reviewed medical records of children with retinoblastoma who were treated at our center from June 2002 to February 2008. Twenty-eight eyes from 27 patients were enucleated. Median age at diagnosis was 1.1 years (range, 0.3-6.3 years). Twenty-six eyes (93%) had advanced disease (RE groups IV and V). Seventeen patients (61%) had unilateral retinoblastoma, and 11 (39%) had bilateral retinoblastoma. The median time from diagnosis to enucleation was 0.45 months (range, 0-45 months; mean, 4.4 months) and was longer for patients with bilateral retinoblastoma (median, 2.2 vs. 0.2 months; P = 0.034). Twenty enucleated eyes (71%) did not show high-risk pathologic features. Seventeen eyes with advanced intraocular disease were enucleated atthe time of presentation, whereas chemoreduction was attempted for the other 19 eyes with advanced intraocular disease. Enucleation was then recommended for nine (47%) of those eyes. Enucleation at the time of diagnosis was feasible for most patients with advanced disease. Attempted salvage of eyes with advanced disease is justified, particularly in patients with bilateral disease. We were able to salvage almost half of these eyes. We hope our study provides new insights for counseling patients.

AB - Despite multiple advances in the management of retinoblastoma, enucleation remains an essential therapeutic modality. We studied patients who underwent enucleation at the King Hussein Cancer Center in Jordan. We retrospectively reviewed medical records of children with retinoblastoma who were treated at our center from June 2002 to February 2008. Twenty-eight eyes from 27 patients were enucleated. Median age at diagnosis was 1.1 years (range, 0.3-6.3 years). Twenty-six eyes (93%) had advanced disease (RE groups IV and V). Seventeen patients (61%) had unilateral retinoblastoma, and 11 (39%) had bilateral retinoblastoma. The median time from diagnosis to enucleation was 0.45 months (range, 0-45 months; mean, 4.4 months) and was longer for patients with bilateral retinoblastoma (median, 2.2 vs. 0.2 months; P = 0.034). Twenty enucleated eyes (71%) did not show high-risk pathologic features. Seventeen eyes with advanced intraocular disease were enucleated atthe time of presentation, whereas chemoreduction was attempted for the other 19 eyes with advanced intraocular disease. Enucleation was then recommended for nine (47%) of those eyes. Enucleation at the time of diagnosis was feasible for most patients with advanced disease. Attempted salvage of eyes with advanced disease is justified, particularly in patients with bilateral disease. We were able to salvage almost half of these eyes. We hope our study provides new insights for counseling patients.

UR - http://www.scopus.com/inward/record.url?scp=77956182340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956182340&partnerID=8YFLogxK

U2 - 10.1007/s10792-010-9370-3

DO - 10.1007/s10792-010-9370-3

M3 - Article

C2 - 20424888

AN - SCOPUS:77956182340

VL - 30

SP - 407

EP - 414

JO - International Ophthalmology

JF - International Ophthalmology

SN - 0165-5701

IS - 4

ER -